Lunai Bioworks (LNAI) Depreciation & Amortization (CF) (2013 - 2026)
Lunai Bioworks (LNAI) recorded quarterly Depreciation & Amortization (CF) of $19634.0 in Q1 2026, up 73.26% quarter-over-quarter from $11332.0 in Q4 2025, and down 38.6% on a YoY basis from $31975.0 in Q1 2025.
Lunai Bioworks (LNAI) Depreciation & Amortization (CF) (2013 - 2026) Analysis & Trends
Lunai Bioworks' Depreciation & Amortization (CF) history runs 14 years deep, the most recent figure standing at $19634.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 38.6% year-over-year to $19634.0; the TTM figure through Mar 2026 stood at $105114.0 (down 17.62% YoY), while the FY2025 annual figure was $129095.0, down 31.49% from the prior year.
- Depreciation & Amortization (CF) was $19634.0 for Q1 2026 at Lunai Bioworks, up from $11332.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $41522.0 in Q3 2025 to a low of $11332.0 in Q4 2025.
- Historically, Depreciation & Amortization (CF) has averaged $29234.7 across 5 years, with a median of $30305.0 in 2024.
- Biggest YoY gain for Depreciation & Amortization (CF) was 28.21% in 2025; the steepest drop was 64.71% in 2025.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $28844.0 in 2022, then rose by 14.97% to $33162.0 in 2023, then dropped by 3.18% to $32109.0 in 2024, then sank by 64.71% to $11332.0 in 2025, then jumped by 73.26% to $19634.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $19634.0 (Q1 2026), $11332.0 (Q4 2025), and $41522.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Lunai Bioworks | 95.85 Mn | 92.70 Mn | 20,942.00 | 19,634.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 19,634.00 |
| Mar 31, 2026 | 19,634.00 |
| Dec 31, 2025 | 11,332.00 |
| Dec 31, 2025 | 11,332.00 |
| Sep 30, 2025 | 41,522.00 |
| Sep 30, 2025 | 41,522.00 |
| Jun 30, 2025 | 32,626.00 |
| Jun 30, 2025 | 32,626.00 |
| Mar 31, 2025 | 31,975.00 |
| Mar 31, 2025 | 31,975.00 |
| Dec 31, 2024 | 32,109.00 |
| Dec 31, 2024 | 32,109.00 |
| Sep 30, 2024 | 32,385.00 |
| Sep 30, 2024 | 32,385.00 |
| Jun 30, 2024 | 31,132.00 |
| Jun 30, 2024 | 31,132.00 |
| Mar 31, 2024 | 30,305.00 |
| Mar 31, 2024 | 30,305.00 |
| Dec 31, 2023 | 33,162.00 |
| Dec 31, 2023 | 33,162.00 |